BLIS Technologies Limited

Equities

BLT

NZBLTE0002S8

Pharmaceuticals

End-of-day quote New Zealand S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
0.017 NZD -.--% Intraday chart for BLIS Technologies Limited -5.56% -10.53%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
New Zealand Shares Close Flat on Monday; Blis Technologies Upgrades Fiscal 2024 Guidance MT
Blis Technologies Upgrades Fiscal 2024 Guidance MT
BLIS Technologies Limited Provides Latest Guidance for the Year Ended 31 March 2024 CI
Blis Technologies Reports Profitable Third Quarter MT
BLIS Technologies Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
BLIS Technologies Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
BLIS Technologies Limited Reports Earnings Results for the Half Year Ended September 30, 2022 CI
BLIS Technologies Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Probi AB Completes First Production Batches of Dairy-Free BLIS K12 CI
BLIS Technologies Limited Reports Earnings Results for the Half Year Ended September 30, 2021 CI
Blis Technologies and Probi AB Signs a Licensing and Distribution Agreement CI
Blis Technologies Limited Reports Earnings Results for the Full Year Ended March 31, 2021 CI
Roolife : Launches Blis Technologies’ Online Store on China’s Tmall Global; Shares Fall 4% MT
RooLife Group Ltd and Blis Technologies Ltd Launches Flagship Store on China's Tmall Global CI
Blis Technologies Limited Reports Earnings Results for the Half Year Ended September 30, 2020 CI
Blis Technologies Limited Announces Retirement of Graeme Boyd from the Board CI
Blis Technologies Limited Reports Earnings Results for the Full Year Ended March 31, 2020 CI
Blis Technologies Launches a New Product UltraBLIS CI
Blis Technologies Limited Reports Earnings Results for the Half Year Ended September 30, 2019 CI
Blis Technologies Limited Reports Earnings Results for the Full Year Ended March 31, 2019 CI
BLIS Technologies Limited Announces Retirement of Veronica Aris as A Director CI
BLIS Technologies Limited Reports Unaudited Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Earnings Guidance for the Year 2019 CI
BLIS Technologies Limited Announces Board Appointments CI
BLIS Technologies Limited Reports Unaudited Consolidated Earnings Results for the Six Months Ended September 30, 2017 CI
BLIS Technologies Limited Provides Earnings Guidance for the Six Months Ending September 30, 2017 and Full Year Ending March 31, 2018 CI
Chart BLIS Technologies Limited
More charts
Blis Technologies Limited is a New Zealand-based manufacturer of advanced probiotic strains. The Company’s principal activity is developing healthcare products based on strains of bacteria that produce bacteriocin activity for sale in New Zealand and overseas. It delivers probiotic solutions for specific health targets, including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. Its probiotic portfolio includes BLIS K12, BLIS M18 and BLIS Q24. It sells ingredients and finishes goods to manufacturers and wholesale customers. The BLIS K12 (Streptococcus salivarius K12) is a probiotic to support the mouth and throat. The BLIS M18 (Streptococcus salivarius M18) is a probiotic to support teeth and gum health. The BLIS Q24 balances and restores the skin microbiome, restoring its natural health, clarity and radiance. The Company’s products are sold throughout New Zealand and in Australia, Asia, Europe and the United States.
More about the company
  1. Stock Market
  2. Equities
  3. BLT Stock
  4. News BLIS Technologies Limited
  5. Blis Technologies Upgrades Fiscal 2024 Guidance